Drug intelligence / Profile preview

MK-6837

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

MK-6837 is an investigational drug under development by Merck for the treatment of advanced or metastatic solid tumors. It is being evaluated as both a monotherapy and in combination with pembrolizumab (an anti-PD-1 monoclonal antibody) in patients whose cancers have not responded to conventional therapy. The drug is administered intravenously as an infusion and is currently in Phase 1 clinical trials, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy. The precise mechanism of action for MK-6837 has not been publicly disclosed[1][2][5][7].

Beyond the preview

Go deeper on MK-6837.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-6837.

Explore the full profile